Gut-specific-α4β7 integrin antibody (vedolizumab and etrolizumab) and IL-12/IL-23 inhibitors (ustekinumab and risankizumab) have shown therapeutic effect to patients who have refractory IBD or lose response to anti-TNF treatment (16–18). The gene discussed is TNF; the disease is irritable bowel syndrome.